UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of April 2024
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
 
GSK plc (the ‘Company’)
 
 
Transaction notification
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
 
Emma Walmsley
b)
Position/status
Chief Executive Officer
 
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2900
770
 
 
 
£16.2900
1,279
 
 
 
£16.2900
1,446
 
 
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume
 
Price
 
3,495
 
£16.2900
 
e)
Date of the transaction
2024-04-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
 
Dr Hal Barron
b)
Position/status
 
Non-Executive Director
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares (‘ADSs’)
 
ISIN: US37733W2044
 
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 11 April 2024 on ADSs held in the Company’s Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
$40.8000
427
 
 
 
 
 
 
 
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume
 
Price
 
 
e)
Date of the transaction
 
2024-04-16
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
Julie Brown
 
b)
Position/status
Chief Financial Officer
 
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2900
551
 
 
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume
 
Price
 
 
e)
Date of the transaction
2024-04-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
Diana Conrad
 
b)
Position/status
Chief People Officer
 
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2900
120
 
 
 
£16.2900
232
 
 
 
£16.2900
364
 
 
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume
 
Price
 
716
 
£16.2900
 
e)
Date of the transaction
2024-04-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
James Ford
 
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
 
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2900
148
 
 
 
£16.2900
226
 
 
 
£16.2900
369
 
 
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume
 
Price
 
743
 
£16.2900
 
e)
Date of the transaction
2024-04-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
Sally Jackson
 
b)
Position/status
SVP, Global Communications and CEO Office
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
 
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2900
69
 
 
 
£16.2900
141
 
 
 
£16.2900
228
 
 
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume
 
Price
 
438
 
£16.2900
 
e)
Date of the transaction
2024-04-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
 
Luke Miels
b)
Position/status
 
Chief Commercial Officer
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2900
253
 
 
 
£16.2900
545
 
 
 
£16.2900
687
 
 
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume
 
Price
 
1,485
 
£16.2900
 
e)
Date of the transaction
2024-04-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
 
Shobie Ramakrishnan
b)
Position/status
 
Chief Digital and Technology Officer
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares (‘ADSs’)
 
ISIN: US37733W2044
b)
Nature of the transaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 11 April 2024 on ADSs held in the Company’s Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
$40.8000
26
 
 
 
$40.8000
112
 
 
 
$40.8000
175
 
 
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume
 
Price
 
313
 
$40.8000
 
e)
Date of the transaction
2024-04-16
 
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
David Redfern
 
b)
Position/status
President Corporate Development
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2900
167
 
 
 
£16.2900
315
 
 
 
£16.2900
437
 
 
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume
 
Price
 
919
 
£16.2900
 
e)
Date of the transaction
2024-04-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
Regis Simard
 
b)
Position/status
President, Global Supply Chain
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2900
152
 
 
 
£16.2900
253
 
 
 
£16.2900
526
 
 
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume
 
Price
 
931
 
£16.2900
 
e)
Date of the transaction
2024-04-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
Philip Thomson
 
b)
Position/status
President, Global Affairs
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
 
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2900
105
 
 
 
£16.2900
165
 
 
 
£16.2900
294
 
 
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume
 
Price
564
 
£16.2900
 
e)
Date of the transaction
2024-04-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
Deborah Waterhouse
 
b)
Position/status
CEO, ViiV Healthcare and President, Global Health, GSK
 
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£16.2900
111
 
 
 
£16.2900
403
 
 
 
£16.2900
455
 
 
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume
 
Price
 
969
 
£16.2900
 
e)
Date of the transaction
2024-04-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
Tony Wood
 
b)
Position/status
Chief Scientific Officer
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
 
c)
Price(s) and volume(s)
 
 
 
 
Price(s)
Volume(s)
 
 
 
£16.2900
191
 
 
 
£16.2900
561
 
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
 
Aggregated volume
 
Price
 
752
 
£16.2900
 
e)
Date of the transaction
2024-04-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
 
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
 
Name
 
Emma Walmsley
 
b)
 
Position/status
 
Chief Executive Officer
c)
 
Initial notification/amendment
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GSK plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN: GB00BN7SWP63
 
b)
 
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024 on Ordinary Shares held in the Company’s Performance Share Plan subject to a 2-year holding period
 
c)
 
Price(s) and volume(s)
 
Price(s)
Volume(s)
£16.2900
6863.859
d)
 
Aggregated information
Aggregated volume Price
N/A (single transaction)
 
e)
 
Date of the transaction
 
2024-04-16
 
f)
 
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: April 17, 2024
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc